All Eyes on Human Genome Sciences (Nasdaq: HGSI) Benlysta FDA Approval Decision

FOR IMMEDIATE RELEASE
Henderson, Nevada, United States of America (Free-Press-Release.com) February 25, 2011 -- Stock Trading Video on HGSI Human Genome Sciences FDA, HGSI Human Genome Sciences FDA Human Genome Sciences Benlysta® Drug Approval Decision for Lupus Patients. Human Genome Sciences (NASDAQ Symbol: HGSI)

Human Genome Sciences and its partner GlaxoSmithKline PLC are waiting for a Food and Drug Administration decision on Benlysta. An advisory panel said in November that the drug should be approved, but the FDA said it needed more information. After the companies submitted that information, the FDA said it needed three more months to make a decision. The ruling is scheduled to come by March 10. We've been telling our traders that it will be on or before March 10, 2011 if the FDA decides to provide approval.

Full Video:
http://www.stockmarketfunding.com/Videos/Stocks/HGSI/All-Eyes-on-Human-Genome-Sciences-Benlysta-FDA.aspx

benlysta     benlysta fda     HGSI     hgsi benlysta     hgsi stock     human genome     human genome sciences     stock hgsi